<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Eptifibatide</id>
	<title>Eptifibatide - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikem.org/w/index.php?action=history&amp;feed=atom&amp;title=Eptifibatide"/>
	<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Eptifibatide&amp;action=history"/>
	<updated>2026-04-15T23:31:48Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.38.2</generator>
	<entry>
		<id>https://wikem.org/w/index.php?title=Eptifibatide&amp;diff=299734&amp;oldid=prev</id>
		<title>Elcatracho: /* See Also */</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Eptifibatide&amp;diff=299734&amp;oldid=prev"/>
		<updated>2021-03-06T03:07:33Z</updated>

		<summary type="html">&lt;p&gt;&lt;span dir=&quot;auto&quot;&gt;&lt;span class=&quot;autocomment&quot;&gt;See Also&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;en&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Older revision&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Revision as of 03:07, 6 March 2021&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l72&quot;&gt;Line 72:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Line 72:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==See Also==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt; &lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*[[Antiplatelet medications]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-side-deleted&quot;&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;*[[Antiplatelet agent reversal]]&lt;/ins&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==References==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==References==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</summary>
		<author><name>Elcatracho</name></author>
	</entry>
	<entry>
		<id>https://wikem.org/w/index.php?title=Eptifibatide&amp;diff=187166&amp;oldid=prev</id>
		<title>Jonwarren: Creation of page</title>
		<link rel="alternate" type="text/html" href="https://wikem.org/w/index.php?title=Eptifibatide&amp;diff=187166&amp;oldid=prev"/>
		<updated>2018-07-26T03:53:26Z</updated>

		<summary type="html">&lt;p&gt;Creation of page&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;==Administration==&lt;br /&gt;
*Type: [[Antiplatelet]]&lt;br /&gt;
*Dosage Forms: INJ&lt;br /&gt;
*Routes of Administration: IV&lt;br /&gt;
*Common Trade Names: Integrilin&lt;br /&gt;
&lt;br /&gt;
==Adult Dosing==&lt;br /&gt;
===[[Acute Coronary Syndrome]]===&lt;br /&gt;
*2 mcg/kg/min IV&lt;br /&gt;
**Start 180 mcg/kg up to 22.6 mg IV x1&lt;br /&gt;
**Max: 15 mg/h infusion&lt;br /&gt;
===PCI===&lt;br /&gt;
* 2 mcg/kg/min IV&lt;br /&gt;
**Start 180 mcg/kg up to 22.6 mg IV x1&lt;br /&gt;
**Max: 15 mg/h infusion&lt;br /&gt;
**Repeat bolus x1 10 min after initial dose&lt;br /&gt;
&lt;br /&gt;
==Pediatric Dosing==&lt;br /&gt;
Safety/efficacy not established in pediatric patients&lt;br /&gt;
&lt;br /&gt;
==Special Populations==&lt;br /&gt;
===[[Drug pregnancy categories|Pregnancy Rating]]===&lt;br /&gt;
*Benefits outweigh risks during pregnancy&lt;br /&gt;
*Risk of maternal hemorrhage during delivery&lt;br /&gt;
*Risk of fetal bleeding&lt;br /&gt;
&lt;br /&gt;
===Lactation risk===&lt;br /&gt;
*May use when breastfeeding&lt;br /&gt;
&lt;br /&gt;
===Renal Dosing===&lt;br /&gt;
*Adult: &lt;br /&gt;
**CrCl &amp;lt;50: Decrease infusion to 1 mcg/kg/min, max 7.5 mg/h&lt;br /&gt;
**HD: Avoid use&lt;br /&gt;
*Pediatric: Unavailable&lt;br /&gt;
&lt;br /&gt;
===Hepatic Dosing===&lt;br /&gt;
*Adult: Not defined&lt;br /&gt;
*Pediatric: Unavailable&lt;br /&gt;
&lt;br /&gt;
==Contraindications==&lt;br /&gt;
*Allergy to class/drug&lt;br /&gt;
*Bleeding diathesis history&lt;br /&gt;
*Active abnormal bleeding w/in 30 days&lt;br /&gt;
*Major surgery w/in 6 weeks&lt;br /&gt;
*[[Stroke]] w/in 30 days&lt;br /&gt;
*Hemorrhagic stroke history&lt;br /&gt;
*Platelet &amp;lt; 100,000&lt;br /&gt;
*SBP &amp;gt; 200, DBP &amp;gt; 110&lt;br /&gt;
*Dialysis&lt;br /&gt;
&lt;br /&gt;
==Adverse Reactions==&lt;br /&gt;
===Serious===&lt;br /&gt;
*Bleeding&lt;br /&gt;
*[[Intracranial hemorrhage]]&lt;br /&gt;
*[[Thrombocytopenia]]&lt;br /&gt;
*[[Anaphylaxis]]&lt;br /&gt;
&lt;br /&gt;
===Common===&lt;br /&gt;
*Bleeding&lt;br /&gt;
*[[Hypotension]]&lt;br /&gt;
&lt;br /&gt;
==Pharmacology==&lt;br /&gt;
*Half-life: 2.5 hours&lt;br /&gt;
*Metabolism: Other&lt;br /&gt;
*Excretion: Urine 50%&lt;br /&gt;
&lt;br /&gt;
==Mechanism of Action==&lt;br /&gt;
*Reversibly binds to platelet glycoprotein IIb/IIIa receptors, reducing platelet aggregation&lt;br /&gt;
&lt;br /&gt;
==Comments==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==See Also==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
==References==&lt;br /&gt;
&amp;lt;references/&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Category:Pharmacology]]&lt;/div&gt;</summary>
		<author><name>Jonwarren</name></author>
	</entry>
</feed>